Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.

Loh KP, Baran A, Lee CY, Alshaibani A, Rutherford SC, Hu J, Casulo C, Barr PM, Friedberg JW, Reagan PM.

Leuk Lymphoma. 2019 Jul 8:1-4. doi: 10.1080/10428194.2019.1639172. [Epub ahead of print] No abstract available.

PMID:
31282781
2.

Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib.

Tomlinson SB, Sandwell S, Chuang ST, Johnson MD, Vates GE, Reagan PM.

Leuk Res. 2019 Aug;83:106164. doi: 10.1016/j.leukres.2019.05.014. Epub 2019 May 28. No abstract available.

PMID:
31226541
3.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS.

Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.

PMID:
30518502
4.

Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.

David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):781-787. doi: 10.1016/j.clml.2018.08.014. Epub 2018 Aug 29.

PMID:
30262330
5.

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen R, Candia AF, Coffman RL, Levy R.

Cancer Discov. 2018 Oct;8(10):1258-1269. doi: 10.1158/2159-8290.CD-18-0743. Epub 2018 Aug 28.

PMID:
30154192
6.

Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.

Rodgers TD, Reagan PM.

Expert Opin Emerg Drugs. 2018 Jun;23(2):111-122. doi: 10.1080/14728214.2018.1479396. Epub 2018 Jun 6. Review.

PMID:
29781323
7.

Current treatment of double hit and double expressor lymphoma.

Reagan PM, Davies A.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):295-297. doi: 10.1182/asheducation-2017.1.295. Review.

8.

Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions.

Reagan PM, Friedberg JW.

Oncology (Williston Park). 2017 May 15;31(5):402-11. Review.

9.

Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve.

Reagan PM, Barr PM.

Lancet Haematol. 2017 Apr;4(4):e152-e153. doi: 10.1016/S2352-3026(17)30040-6. Epub 2017 Mar 15. No abstract available.

PMID:
28314698
10.

Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma.

Reagan PM, Baran A, Kelly JL, Barr PM, Casulo C, Chengazi VU, Friedberg JW.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):322-328.e2. doi: 10.1016/j.clml.2016.03.014. Epub 2016 Apr 2.

PMID:
27130328
11.

Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.

Reagan PM, Friedberg JW.

Curr Treat Options Oncol. 2015 Jul;16(7):32. doi: 10.1007/s11864-015-0351-7. Review.

PMID:
26031546
12.

Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.

Reagan PM, Friedberg JW.

Future Oncol. 2015;11(10):1543-53. doi: 10.2217/fon.15.1. Review.

PMID:
25963431
13.

The snow-shoveler's ST elevation myocardial infarction.

Janardhanan R, Henry Z, Hur DJ, Lin CM, Lopez D, Reagan PM, Rudnick SR, Koshko TJ, Keeley EC.

Am J Cardiol. 2010 Aug 15;106(4):596-600. doi: 10.1016/j.amjcard.2010.03.075.

Supplemental Content

Loading ...
Support Center